Michael Freeman
Stock Analyst at Raymond James
(2.82)
# 1,878
Out of 5,072 analysts
6
Total ratings
60%
Success rate
40.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Freeman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Assumes: Outperform | $14 | $7.67 | +82.53% | 1 | Jun 11, 2025 | |
| TECX Tectonic Therapeutic | Reinstates: Outperform | $76 | $21.39 | +255.31% | 1 | Jun 11, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $37 | $21.17 | +74.78% | 1 | Jun 11, 2025 | |
| IRON Disc Medicine | Reinstates: Strong Buy | $89 | $93.75 | -5.07% | 1 | Jun 11, 2025 | |
| RNA Avidity Biosciences | Initiates: Strong Buy | $65 | $71.56 | -9.17% | 1 | Jun 11, 2025 | |
| BHC Bausch Health Companies | Initiates: Market Perform | $8 | $6.25 | +28.00% | 1 | Jul 10, 2024 |
Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $7.67
Upside: +82.53%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $21.39
Upside: +255.31%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $21.17
Upside: +74.78%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $93.75
Upside: -5.07%
Avidity Biosciences
Jun 11, 2025
Initiates: Strong Buy
Price Target: $65
Current: $71.56
Upside: -9.17%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $6.25
Upside: +28.00%